Jenkin X Forward Crack & Cross in One Forward-Firing IVL Platform · First Release of China Multicenter Clinical Data
SHUNMEI MEDICAL
Jenkin X
Forward Crack & Cross in One
Forward-Firing IVL Platform · First China Multicenter Clinical Data
Single-use coronary intravascular lithotripsy microcatheter (Jenkin X)
When a Balloon Cannot Pass,
How Does Lithotripsy Crack Its Way Forward?
In the cath lab, calcium is often the most concrete of walls. The guidewire crosses, but a conventional balloon will not — and balloon-based IVL is shut out too, because its premise is that the balloon must cross before therapy can begin.
Jenkin X takes a different route: energy is no longer released circumferentially around a balloon but fired forward from the catheter tip. It does not rely on balloon expansion for positioning and does not need to cross the lesion first — advancing through the vessel, it fractures the calcium ahead and opens a path for itself.
This is not a concept demonstration. The China multicenter clinical trial has just been completed, and the clinical data were presented at TCT 2026 in San Diego.
CLINICAL HIGHLIGHTS
54 Cases at a Glance
|
100% Procedural Success 54/54 · target 85% |
100% 30-Day MACE-Free 54/54 · target 84.4% |
|
|
|
|
100% Device Delivery Rate Calcium fracture rate also 100% |
98.1% Device Success 53/54 · core lab QCA |
Prospective, multicenter, single-arm objective performance criteria study | Independent angiographic core laboratory QCA | Protocol SM-GM-JENKIN-2026-1
The Real Challenge of Calcium: Crossing, Not Cracking
Every approved IVL device today is balloon-based, and its principal clinical limitation is lesion crossing: the balloon segment must pass the lesion before treatment can start. The 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Coronary Artery Calcified Lesions explicitly treats “IVL balloon unable to cross the lesion” as a contraindication for this class of devices. In the most common and most difficult scenario — guidewire across, balloon will not pass — the balloon-based IVL in the operator's hand is effectively unusable.
The Structural Limit of Balloon-Based IVL
The balloon segment must cross the lesion completely before therapy can begin. The 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Coronary Artery Calcified Lesions explicitly lists “IVL balloon unable to cross the lesion” as a limitation and contraindication for this class of devices. In the most common and most difficult scenario — guidewire across, balloon will not pass — the balloon-based IVL in the operator's hand is effectively unusable.
Complex CTO: guidewire across, yet balloon and microcatheter still cannot pass
PLATFORM
The World's First Forward-Firing IVL Platform
In line with this international trend, Shenzhen Shunmei Medical Co., Ltd. developed a single-use coronary intravascular lithotripsy microcatheter together with its dedicated intravascular lithotripsy energy system. The device uses a micro-balloon design while reorienting the shockwave — from predominantly longitudinal emission to predominantly forward emission — so that calcium ahead of the catheter can be fractured in advance as the device advances.Shunmei Medical is the first manufacturer in the world to obtain CE certification for coronary IVL.
Two Energy Philosophies: Circumferential vs. Forward
|
|
|
|
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balloon-based IVL: circumferential, radial energy
Jenkin X: directed forward energy from the tip
MECHANISM
Four Steps: From “Cannot Pass” to “Passed”
The complete Jenkin X workflow comprises four consecutive steps.
1Engage — tip positioned at the calcified segment
The catheter is advanced over the guidewire until the tip micro-balloon reaches the proximal edge of the calcification. No inflation is required.
2Crack — forward pulses fracture the calcium ahead
Pulses emitted from the tip micro-balloon generate an acoustic pressure wave ahead of the catheter, acting selectively on calcified tissue.
3Cross — fracture and cross in one continuous motion
Under continuous gentle forward force, the fractured calcium gives way and the catheter follows through, opening the lesion.
4Treat — the channel is open; downstream devices are the operator's choice
The lesion can then be treated with a balloon, cutting balloon, atherectomy or balloon-based IVL, leaving the full range of strategy options with the operator.
Catheter delivery → acoustic pressure wave → calcium fracture → lumen expansion, creating a channel for subsequent therapy
CLINICAL EVIDENCE
54-Case China Multicenter Pivotal Study: All Endpoints Met
This section presents the core results of the SM-GM-JENKIN-2026-1 trial across four levels: study design, primary endpoint, imaging gradient, and secondary endpoints with procedural performance. All imaging endpoints were assessed by an independent angiographic core laboratory using quantitative coronary angiography (QCA). The FAS, PPS and SS sets each comprised 54 patients, with no dropouts and no loss to follow-up.
(1) Study Design
|
|
|
|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Primary Endpoint: Met and Exceeded the Preset Target
The primary efficacy endpoint was procedural success, defined as successful crossing of the target lesion and completion of treatment with the study device, immediate post-PCI residual stenosis of the target lesion ≤50% (by independent core laboratory QCA), and no in-hospital MACE. The observed rate was 100% (54/54; Clopper-Pearson 95% CI 93.40–100), above the protocol-specified target of 85%, meeting the statistical criterion for superiority.
(3) Imaging Gradient: Lumen Gain Occurs Before Stenting
Minimum Lumen Diameter, MLD (mm)
|
0.53±0.27 Baseline |
1.44±0.31 Post-preparation |
1.97±0.43 Post-PCI |
Diameter Stenosis, DS (%)
|
78.70±10.20 Baseline |
41.30±7.78 Post-preparation |
15.05±6.01 Post-PCI |
(4) Secondary Endpoints and Procedural Performance
|
|
|
|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Step Recanalization of a Severely Calcified CTO
CASE 1 | Severe calcific subtotal occlusion of the right coronary artery
After the guidewire crossed, a 2.0 mm balloon still would not pass the lesion — precisely the scenario Jenkin X is designed for.
- Jenkin X therapy: multiple shockwave cycles; the catheter tip fractured the calcium and crossed the lesion
- Balloon dilation: the balloon crossed the lesion without resistance and flow was restored
- Stenting: normal flow restored
|
Pre-op: severe calcific subtotal occlusion of the proximal RCA |
Post-op: flow restored in the RCA |
Post-op angiography: good flow restoration in the right coronary artery
Intravascular imaging confirmation: LAD CTO lesion (IVUS)
|
IVUS pre-op: circumferential calcified plaque |
IVUS post-op: marked lumen enlargement |
Case images: original angiographic records from the Jenkin X China multicenter clinical trial (authorized for academic exchange)
From China Clinical Data to the International Stage
At TCT 2026 (San Diego, USA), Jenkin X made its debut. In his presentation, Dr. Mohamed Ayoub of the Heart Center HDZ NRW, Germany, cited the key Jenkin X data: minimum lumen diameter (MLD) improved from 0.53 mm to 1.44 mm, with a device success rate of 98.1%.
From the intracavitary lithotripsy of ShockFast to the forward-firing lithotripsy of Jenkin X, and on to a complete CTO device portfolio — Shunmei Medical continues to bring safer, more efficient and more complete calcified-lesion solutions to operators worldwide.
Shunmei Medical's coronary IVL portfolio continues to bring safer, more efficient and more complete calcified-lesion solutions to operators worldwide.
About Shunmei Medical
Founded in 2009, Shunmei Medical focuses on vascular intervention across five core segments: coronary intervention, structural heart disease, peripheral intervention, neurointervention and anesthesia consumables. Its IVL portfolio addresses lesions in coronary, peripheral and structural heart applications. The company operates five manufacturing bases — Shenzhen, Huizhou, Hunan, Türkiye and Germany — and serves more than 150 countries and regions worldwide. Backed by a comprehensive quality system and innovative product solutions, Shunmei Medical provides full support for clinical procedures around the world.
Disclaimer: This content is provided for academic exchange among healthcare professionals and does not constitute medical advice or a guide to diagnosis or treatment. The clinical data cited derive from a prospective, multicenter, single-arm objective performance criteria trial sponsored by Shenzhen Shunmei Medical Co., Ltd. (protocol SM-GM-JENKIN-2026-1; report SM-GM-JENKIN-CSR20261109, V1.0), with imaging endpoints assessed by an independent core laboratory using QCA. The study was single-arm, enrolled 54 patients, followed patients for 30 days and relied primarily on imaging endpoints; larger, controlled, longer-term studies are still required. Comparisons with other products are for reference only and do not constitute a claim of superiority. Indications, intended use, contraindications and precautions are governed by the officially approved instructions for use in mainland China; use outside mainland China must follow locally approved indications and labeling.
Jenkin X
Forward Crack & Cross in One
Shenzhen Shunmei Medical Co., Ltd.
